Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Patricia Bento da Silva, Débora Leite Campos, Camila Maríngolo Ribeiro, Isabel Cristiane da Silva & Fernando Rogério Pavan. (2017) New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001–2016). Expert Opinion on Therapeutic Patents 27:3, pages 269-282.
Read now
Read now
Articles from other publishers (45)
Mercy A. Okezue & Stephen R. Byrn. (2023) Synthesis, Characterization, and Stability Assessment for the Benzoate, Hydrochloride, Malonate, and Nicotinate Salts of Bedaquiline. Pharmaceuticals 16:2, pages 257.
Crossref
Crossref
Ginenus Fekadu, Tadesse Tolossa, Ebisa Turi, Firomsa Bekele & Getahun Fetensa. (2022) Pretomanid development and its clinical roles in treating tuberculosis. Journal of Global Antimicrobial Resistance 31, pages 175-184.
Crossref
Crossref
Min Qiao, Shanshan Li, Jinfeng Yuan, Weicong Ren, Yuanyuan Shang, Wei Wang, Rongmei Liu, Fuzhen Zhang, Qing Li, Xiao Wu, Jie Lu, Mengqiu Gao & Yu Pang. (2022) Delamanid suppresses CXCL10 expression via regulation of JAK/STAT1 signaling and correlates with reduced inflammation in tuberculosis patients. Frontiers in Immunology 13.
Crossref
Crossref
Saurav Howlader, Min-Jung Kim, M. Rasheduzzaman Jony, Nguyen Phuoc Long, Yong-Soon Cho, Dong-Hyun Kim & Jae-Gook Shin. (2022)
Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation
In Vitro
. Antimicrobial Agents and Chemotherapy 66:10.
Crossref
Crossref
Lehlogonolo N. F. Maphalle, Bozena B. Michniak-Kohn, Modupe O. Ogunrombi & Oluwatoyin A. Adeleke. (2022) Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?. Children 9:8, pages 1120.
Crossref
Crossref
Joaquim Trigo Marquês, Catarina Frazão De Faria, Marina Reis, Diana Machado, Susana Santos, Maria da Soledade Santos, Miguel Viveiros, Filomena Martins & Rodrigo F. M. De Almeida. (2022) In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis. Frontiers in Pharmacology 13.
Crossref
Crossref
Ginenus Fekadu, Kenneth K.W. To & Joyce H.S. You. (2021) WITHDRAWN: Pretomanid for the treatment of Mycobacterium tuberculosis: Evidence on the development and clinical roles. Journal of Infection and Public Health.
Crossref
Crossref
Ivan Bastian, Lisa Shephard & Richard Lumb. (2021) Revised guidelines for Australian laboratories performing mycobacteriology testing. Communicable Diseases Intelligence 44.
Crossref
Crossref
Saeed Khoshnood, Mehdi Goudarzi, Elahe Taki, Atieh Darbandi, Ebrahim Kouhsari, Mohsen Heidary, Moloudsadat Motahar, Melika Moradi & Hadi Bazyar. (2021) Bedaquiline: Current status and future perspectives. Journal of Global Antimicrobial Resistance 25, pages 48-59.
Crossref
Crossref
Matthias Zeller, Susan Bogdanowich-Knipp, Pamela Smith, Dale K. Purcell, Mercy Okezue, Daniel T. Smith, Stephen R. Byrn & Kari L. Clase. (2021) Maleate salts of bedaquiline. Acta Crystallographica Section E Crystallographic Communications 77:4, pages 433-445.
Crossref
Crossref
Katijah Khoza-Shangase & Marina Prodromos. (2021) Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin. South African Journal of Communication Disorders 68:1.
Crossref
Crossref
NirmalKumar Jain. (2021) WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?. Lung India 38:4, pages 303.
Crossref
Crossref
Mercy Okezue, Daniel Smith, Matthias Zeller, Stephen R. Byrn, Pamela Smith, Susan Bogandowich-Knipp, Dale K. Purcell & Kari L. Clase. (2020) Crystal structures of salts of bedaquiline. Acta Crystallographica Section C Structural Chemistry 76:11, pages 1010-1023.
Crossref
Crossref
Razia Gaida, Ilse Truter & Charles A. Peters. (2020) Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis. Southern African Journal of Infectious Diseases 35:1.
Crossref
Crossref
Dzintars Gotham, Lindsay McKenna, Mike Frick & Erica Lessem. (2020) Public investments in the clinical development of bedaquiline. PLOS ONE 15:9, pages e0239118.
Crossref
Crossref
Yadong Du, Chao Qiu, Xiaohong Chen, Jing Wang, Wei Jing, Hongqiu Pan, Wei Chen, Yufeng Liu, Chunxiang Li, Xiu’e Xi, Hongyun Yin, Jianfeng Zeng, Xia Zhang, Tao Xu, Qingfeng Wang, Ru Guo, Jun Wang, Yu Pang & Naihui Chu. (2020) Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clinical Infectious Diseases 71:4, pages 1047-1054.
Crossref
Crossref
C. A. Aranaga, S. Fraile, A. Torres, A. Falco, F. Michelangeli & H. Takiff. (2020) Antimycobacterial and PknB Inhibitory Activities of Venezuelan Medicinal Plants. International Journal of Microbiology 2020, pages 1-7.
Crossref
Crossref
M. Soledade C.S. Santos, Ana Marta Matos, Marina Reis & Filomena Martins. (2020) Lipophilicity assessment of some isoniazid derivatives active against Mycobacterium tuberculosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects 599, pages 124820.
Crossref
Crossref
Vijay Vinayak Chavan, Alpa Dalal, Sharath Nagaraja, Pruthu Thekkur, Homa Mansoor, Augusto Meneguim, Roma Paryani, Pramila Singh, Stobdan Kalon, Mrinalini Das, Gabriella Ferlazzo & Petros Isaakidis. (2020) Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLOS ONE 15:6, pages e0234651.
Crossref
Crossref
Cátia Teixeira, Cristina Ventura, José R. B. Gomes, Paula Gomes & Filomena Martins. (2020) Cinnamic Derivatives as Antitubercular Agents: Characterization by Quantitative Structure–Activity Relationship Studies. Molecules 25:3, pages 456.
Crossref
Crossref
Cristiane França da Costa, Marcus Vinicius Nora de Souza, Maria Cristina da Silva Lourenço, Elaine Soares Coimbra, Guilherme da Silva Lourenço Carvalho, James Wardell, Stephane Lima Calixto & Juliana da Trindade Granato. (2019) Synthesis and SAR Study of Simple Aryl Oximes and Nitrofuranyl Derivatives with Potent Activity Against Mycobacterium tuberculosis. Letters in Drug Design & Discovery 17:1, pages 12-20.
Crossref
Crossref
Steven J. Berthel, Christopher B. Cooper & Nader Fotouhi. 2019. Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis. Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis
1
25
.
Marieke G G Sturkenboom, Noviana Simbar, Onno W Akkerman, Samiksha Ghimire, Mathieu S Bolhuis & Jan-Willem C Alffenaar. (2018) Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clinical Infectious Diseases 67:suppl_3, pages S303-S307.
Crossref
Crossref
Ruoqiong Cao, Garrett Teskey, Hicret Islamoglu, Rachel Abrahem, Shalok Munjal, Karo Gyurjian, Li Zhong & Vishwanath Venketaraman. (2018) Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy 62:11.
Crossref
Crossref
Helen Cox, Jennifer Hughes, John Black & Mark P Nicol. (2018) Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?. The Lancet Infectious Diseases 18:9, pages e282-e287.
Crossref
Crossref
Samantha Wellington & Deborah T. Hung. (2018)
The Expanding Diversity of
Mycobacterium tuberculosis
Drug Targets
. ACS Infectious Diseases 4:5, pages 696-714.
Crossref
Crossref
Mokhitli Morake, Dina Coertzen, Andile Ngwane, Johannes F. Wentzel, Ho Ning Wong, Frans J. Smit, Lyn-Marie Birkholtz, Ray-Dean Pietersen, Bienyameen Baker, Ian Wiid, David D. N'Da & Richard K. Haynes. (2018) Preliminary Evaluation of Artemisinin-Cholesterol Conjugates as Potential Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis. ChemMedChem 13:1, pages 67-77.
Crossref
Crossref
А. G. NАUMOV & А. V. PАVLUNIN. (2018) PERSPECTIVES OF TARGETED CHEMOTHERAPY WITH DELAMANID IN THE TREATMENT REGIMENS OF THOSE WITH MULTIPLE/EXTENSIVE DRUG RESISTANT TUBERCULOSIS. A SUCCESS, CHANCE OR UNCERTAINTY?. TUBERCULOSIS AND LUNG DISEASES 96:11, pages 74-82.
Crossref
Crossref
Meenakshi R. Ramanathan, Crystal K. Howell & James M. Sanders. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
363
376
.
Rocsanna Namdar & Charles A. Peloquin. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
221
253
.
Diogo Vila-Viçosa, Bruno L. Victor, Jorge Ramos, Diana Machado, Miguel Viveiros, Jacek Switala, Peter C. Loewen, Ruben Leitão, Filomena Martins & Miguel Machuqueiro. (2017)
Insights on the Mechanism of Action of INH-C
10
as an Antitubercular Prodrug
. Molecular Pharmaceutics 14:12, pages 4597-4605.
Crossref
Crossref
Lerato Hlaka, Michael-Jon Rosslee, Mumin Ozturk, Santosh Kumar, Suraj P Parihar, Frank Brombacher, Abedawn I Khalaf, Katharine C Carter, Fraser J Scott, Colin J Suckling & Reto Guler. (2017) Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy. Journal of Antimicrobial Chemotherapy 72:12, pages 3334-3341.
Crossref
Crossref
Naser Al-Tannak & Oludotun Phillips. (2017) Antimycobacterial Activities of N-Substituted-Glycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound. Scientia Pharmaceutica 85:4, pages 34.
Crossref
Crossref
Fernando Alcaide, Jaime Esteban, Julià González-Martin & Juan-José Palacios. (2017) Methods for determining the antimicrobial susceptibility of mycobacteria. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:8, pages 527-533.
Crossref
Crossref
Fernando Alcaide, Jaime Esteban, Julià González-Martin & Juan-José Palacios. (2017) Métodos de determinación de sensibilidad a los antimicrobianos en micobacterias. Enfermedades Infecciosas y Microbiología Clínica 35:8, pages 529-535.
Crossref
Crossref
Jose A. Caminero, Alberto Piubello, Anna Scardigli & Giovanni Battista Migliori. (2017) Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. European Respiratory Journal 50:1, pages 1700648.
Crossref
Crossref
Diana Quan, Gayathri Nagalingam, Richard Payne & James A. Triccas. (2017) New tuberculosis drug leads from naturally occurring compounds. International Journal of Infectious Diseases 56, pages 212-220.
Crossref
Crossref
Moloko C. Cholo, Maborwa T. Mothiba, Bernard Fourie & Ronald Anderson. (2017) Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. Journal of Antimicrobial Chemotherapy 72:2, pages 338-353.
Crossref
Crossref
Meng-Yu Chen, Yi-Chun Lo, Wan-Chin Chen, Kwei-Feng Wang & Pei-Chun Chan. (2017) Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan. PLOS ONE 12:1, pages e0170980.
Crossref
Crossref
Neduri V. Balaji, Bollikolla Hari Babu, Gottumukkala V. Subbaraju, Kurre Purna Nagasree & Muthyala Murali Krishna Kumar. (2017) Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents. Bioorganic & Medicinal Chemistry Letters 27:1, pages 11-15.
Crossref
Crossref
Amber Kunkel, Frank G. Cobelens & Ted Cohen. (2016) Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 13:10, pages e1002142.
Crossref
Crossref
Dede K.W. Man, Michael Y.T. Chow, Luca Casettari, Mercedes Gonzalez-Juarrero & Jenny K.W. Lam. (2016) Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Advanced Drug Delivery Reviews 102, pages 21-32.
Crossref
Crossref
Rashmirekha Pati, Rojalin Sahu, Jagannath Panda & Avinash Sonawane. (2016) Encapsulation of zinc-rifampicin complex into transferrin-conjugated silver quantum-dots improves its antimycobacterial activity and stability and facilitates drug delivery into macrophages. Scientific Reports 6:1.
Crossref
Crossref
Tim R. Blower, Benjamin H. Williamson, Robert J. Kerns & James M. Berger. (2016)
Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from
Mycobacterium tuberculosis
. Proceedings of the National Academy of Sciences 113:7, pages 1706-1713.
Crossref
Crossref
Jane Andrews. (2016) To be or not to be exclusive: the sutezolid story. The Lancet Global Health 4:2, pages e89-e90.
Crossref
Crossref